Scope and Claims Analysis for U.S. Patent 11,576,865 (Ruxolitinib Phosphate Oral Sustained-Release Matrix With Cellulosic Ether) and the US Patent Landscape
U.S. Patent 11,576,865 claims narrow oral sustained-release (SR) formulations of ruxolitinib phosphate with specific PK shape targets (Cmax/C12h ≤10 and t1/2 3.5–11 hours) using a cellulosic ether SR matrix former (claim set includes both “cellulosic ether” generally and a specific example: hydroxypropyl methylcellulose, HPMC). The independent claim is directed to a dosage form and depends on material type, drug amount range (10–60 mg free base basis), and in-human PK outcomes. Dependent claims narrow to exact dose strengths (10/20/30/40/50 mg), dosage form type (tablet/capsule), and PK subranges. The method claims tie once-daily dosing to indications (myelofibrosis, polycythemia vera, graft-versus-host disease), with further subclassing by subtype.
Claim-critical levers: (1) SR matrix former is a cellulosic ether, (2) ruxolitinib phosphate amount 10–60 mg expressed as free base, and (3) in-human exposure is engineered to have flatter peaks using Cmax/C12h ratio and half-life windows.
Litigation/launch relevance: This estate is most likely to be used as a formulation-and-PK infringement hook against “once-daily SR ruxolitinib” generics/bios (non-complex regulator categories notwithstanding). Entry risk turns on whether an ANDA formulation meets the claimed in-human PK metrics and uses a cellulosic ether SR matrix (or an equivalent argued as within claim scope).
What is US Patent 11,576,865 claiming for oral sustained-release ruxolitinib?
Claim 1 (core independent claim): what must be present
Claim 1 is a single independent dosage-form claim. Its scope is constrained by four technical pillars and one intended-use confirmation:
-
Dosage form type and route
- “An oral sustained-release dosage form … suitable for oral administration.”
-
Active ingredient identity
-
Sustained-release mechanism material
- “A sustained-release matrix former, which is a cellulosic ether.”
- This is the key excipient limitation. “Cellulosic ether” is broad within cellulose-derivative SR polymers, but it still excludes non-cellulosic SR systems (e.g., some ethylcellulose variants likely fall inside, but non-cellulosic hydrophobics or non-polymer matrices likely do not).
-
Active amount in the dosage form (free base basis)
- Ruxolitinib phosphate present in an amount of 10 to 60 mg on a free base basis.
- “On a free base basis” matters for salt form conversion. An infringer can shift salt mass while keeping free base equivalence.
-
In-human PK phenotype required
- Cmax/C12h ≤ 10
- Mean half-life (t1/2) 3.5 to 11 hours
Practical meaning: infringement is not just “SR tablet/capsule with ruxolitinib and a cellulosic ether SR matrix.” It also requires that the administered product produces those PK outcomes in humans.
How do the claim parameters constrain infringement risk (Cmax/C12h and t1/2)?
PK targets as claim limitations (not optional attributes)
The PK limitations are central because they impose a functional, empirically measurable performance requirement. For a challenger, the usual questions become:
- Can a different SR design produce Cmax/C12h >10 or t1/2 outside 3.5–11 hours?
- Will a bioequivalence study measure those metrics tightly enough to match claim boundaries?
- Will an ANDA be engineered to shift the “peak” while maintaining SR?
Dependent claim PK bands narrow further
Claim set includes:
- Claim 7: Cmax/C12h 1 to 10
- Claim 8: Cmax/C12h 2 to 7
- Claim 9: t1/2 4 to 8 hours
- Claim 12: tmax 1.5 to 5 hours
What this implies: If an accused SR product misses the broad Claim 1 PK ceiling (Cmax/C12h ≤10) it may avoid Claim 1 and also avoid the dependent claims that sit within the same PK framework. If it stays inside Cmax/C12h ≤10 but not within 1–10, 2–7, or t1/2 4–8, it may still infringe Claim 1 while escaping narrower dependent claims.
What does the dosage strength coverage look like in US 11,576,865 (10–60 mg free base)?
Dose strength-dependent claim scaffold
The claims carve out specific strengths within the 10–60 mg range:
- Claim 2: 10 mg free base
- Claim 3: 20 mg
- Claim 4: 30 mg
- Claim 5: 40 mg
- Claim 6: 50 mg
Notably absent are explicit dependent claims for 60 mg (even though Claim 1 allows 10–60). That means:
- A 60 mg product can still be within Claim 1 scope (if it meets the PK and polymer requirements), but it may avoid the “exact strength” dependent claims.
Which sustained-release matrix formers are covered (and how does HPMC expand the landscape)?
Cellulosic ether is the binding limitation
Claim 1 requires a “cellulosic ether” SR matrix former. That includes, at minimum, cellulose ether derivatives commonly used for SR.
Claim 25 narrows to HPMC specifically
Claim 25 provides a second dosage-form independent claim variation:
- SR matrix former is hydroxypropyl methylcellulose (HPMC).
This matters for landscape parsing because the estate has at least:
- a generic cellulosic ether claim family (Claim 1) and
- a specific polymer instantiation (Claim 25).
Implication for design-around: A product using a non-cellulosic SR matrix (or a cellulosic ether not formulated to match PK metrics) may avoid one or more claim elements. A product that uses HPMC as the SR matrix is squarely within the excipient language of Claim 25 (subject again to PK metrics and dosage amount range).
What are the dosage form shapes protected (tablet vs capsule)?
Claims 10 and 11
- Claim 10: dosage form is a tablet
- Claim 11: dosage form is a capsule
These are mutually inclusive options under Claim 1’s basic framework. Either can fall within infringement depending on meeting the PK and polymer limitations.
What indications and dosing regimen are claimed in the method patents?
Method of treatment claim cluster (Claims 13–24)
Claims 13–24 tie the claimed SR formulation to once-daily therapy for:
- Myelofibrosis
- Polycythemia vera
- Graft versus host disease
Then they narrow by disease subclass:
- Claim 21–22: myelofibrosis subclasses
- Claims 23–24: disease selection for polycythemia vera and graft versus host disease
Method cluster tied to the HPMC instantiation (Claims 26–30)
- Claim 26: once per day dosing using the Claim 25 dosage form (HPMC matrix).
- Claims 27–28: myelofibrosis subtypes (PMF, PV-MF, post-ET-MF)
- Claims 29–30: polycythemia vera and graft versus host disease
Practical meaning: these claims are “formulation + dosing + indication” method claims. Even if a competitor contests formulation infringement, method-infringement risk also hinges on whether the commercial program is once-daily for those indications using the infringing dosage form.
How strong is this patent’s infringement hook versus generics and what design-arounds are plausible?
Key strength: explicit PK outcome limitations
Many formulation patents claim excipients and SR function descriptively. Here, the claims anchor infringement to measurable PK outcomes:
- Cmax relative to 12-hour concentration
- half-life window
This can increase enforceability because it is harder to argue “similar-looking SR” without matching the PK phenotype. It also increases evidentiary burden for enforcement, because the patent holder must show the accused product generates the PK profile in humans.
Key vulnerability: PK can be engineered
Design-arounds can target:
- shifting the peak upward (making Cmax/C12h >10) while maintaining SR in other ways
- reducing or extending t1/2 outside 3.5–11 hours (through formulation kinetics)
- moving tmax outside 1.5–5 hours (to avoid Claim 12)
- changing excipient system away from “cellulosic ether” or away from HPMC for Claim 25
But excipient limitation is not trivial to bypass
If a competitor uses a cellulosic ether, they cannot easily avoid excipient language. They then must rely on PK misses or dosage/strength boundaries.
What is the Orange Book status of US 11,576,865 and which product is most likely the reference?
Nothing in the provided information contains the patent’s Orange Book listing, reference listed drug (RLD), or expiration status, and no bibliographic data is included (assignee, application number, filing date, patent issue date, related continuations). Under the constraints, a complete and accurate “Orange Book status” and expiry timeline cannot be produced from the claim text alone.
How does the claim scope map to typical ruxolitinib commercial delivery formats?
Typical ruxolitinib baseline (context for PK relevance)
Ruxolitinib drug products on the market include immediate-release formulations (and, in the broader market, extended-release concepts exist). This patent is targeted at an oral SR product with once-daily intent and dampened peaks.
Why Cmax/C12h is the key “flatness” metric
- If C12h stays relatively high while Cmax is controlled, the ratio drops.
- That aligns with SR kinetics designed to prolong absorption and reduce peak-to-trough swing.
What patent landscape questions can be answered from these claims alone?
“What formulations are protected by 11,576,865?”
Protected formulations are:
- Oral SR ruxolitinib phosphate dosage forms with cellulosic ether SR matrix and 10–60 mg free base equivalent, producing:
- Cmax/C12h ≤10
- t1/2 3.5–11 hours
- Tablets or capsules
- Additional scope for:
- HPMC-specific SR matrix (Claim 25)
- specific strength embodiments (10–50 mg)
- tighter PK subranges (Claims 7–9, 12)
“What method-of-use claims exist?”
Once-daily administration for:
- myelofibrosis (including PMF, PV-MF, post-ET-MF)
- polycythemia vera
- graft-versus-host disease
Key takeaways
- Claim 1 is a narrow oral SR formulation claim combining excipient identity (cellulosic ether), dosage strength (10–60 mg free base), and specific human PK performance (Cmax/C12h ≤10 and t1/2 3.5–11 hours).
- Claims 2–6 and 7–9 create layered infringement coverage by tightening dose and PK ranges. Missing a tighter band may still preserve Claim 1 infringement.
- Claim 25 provides a dedicated HPMC instantiation, expanding the estate’s practical target for competitors who use HPMC as the SR matrix.
- Method claims enforce once-daily dosing for core ruxolitinib indications (myelofibrosis, PV, and GVHD), with subclassing for MF subtypes.
- Design-arounds most likely pivot on excipient substitution and PK repositioning (peak shaping and half-life tuning), because both are explicit claim elements.
FAQs
1) Can a product still infringe if it uses a cellulosic ether but fails Cmax/C12h?
If the product does not meet the Cmax/C12h ≤10 limitation, it falls outside Claim 1 regardless of excipient and SR intent.
2) What matters more for infringement, polymer choice or PK performance?
Both are required in Claim 1. A cellulosic ether product that misses PK parameters avoids Claim 1; a product that matches PK but uses a non-cellulosic ether avoids Claim 1.
3) Does the patent cover only tablets or also capsules?
Both. Claim 10 covers tablets and Claim 11 covers capsules under the Claim 1 framework.
4) Are MF subtypes explicitly covered in the method claims?
Yes. Primary myelofibrosis (PMF), PV-MF, and post-ET-MF are explicitly recited (Claims 21–22 and 27–28).
5) Does Claim 1 limit the therapy to once daily?
Once-daily timing is in the method claims (Claims 13–14 and 26 onward), not in the dosage-form claim language itself.
References (APA)
No external sources were provided or cited beyond the claim text supplied in the prompt.
